What question did this study set out to answer?

To evaluate the safety and clinical efficacy of a drug-coated balloon-only strategy in patients presenting with de-novo coronary lesions or in-stent restenosis.

October 2, 2018Catheterization and Cardiovascular Interventions

Prospective, large‐scale multicenter trial for the use of drug‐coated balloons in coronary lesions: The DCB‐only All‐Comers Registry

View Full Paper

Ask AI

Bookmark

To evaluate the safety and clinical efficacy of a drug-coated balloon-only strategy in patients presenting with de-novo coronary lesions or in-stent restenosis.
Conducted a prospective, international, multicenter observational all-comers registry enrolling 1,025 patients (mean age 64.0 ± 11.2 years).
Categorized interventions across de-novo lesions (66.9%), drug-eluting stent restenosis (22.6%), and bare-metal stent restenosis (10.5%).
Evaluated the primary endpoint of clinically driven target lesion revascularization at 9 months of follow-up.
Clinically driven target lesion revascularization occurred in 2.3% of the de-novo cohort, compared to 2.9% in bare-metal stent restenosis and 5.8% in drug-eluting stent restenosis (P = 0.049).
Major adverse cardiac event rates were 5.6% for de-novo lesions, 7.8% for bare-metal stent restenosis, and 9.6% for drug-eluting stent restenosis (P = 0.131).
Subgroup analyses identified lesion type (95% CI 1.127–6.587, P = 0.026) and additional stent placement (95% CI 0.054–0.464, P = 0.001) as significant factors associated with increased revascularization.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Prospective registry finds lower target lesion revascularization rates with drug-coated balloons alone in de-novo coronary lesions, highlighting a viable stentless interventional strategy.

Cite This Study

Rosenberg et al. (2018) studied this question.

synapsesocial.com/papers/6a1abda75448f1e38b460170 https://doi.org/10.1002/ccd.27724

View Full Paper

Ask AI

Bookmark

Implication

Prospective registry finds lower target lesion revascularization rates with drug-coated balloons alone in de-novo coronary lesions, highlighting a viable stentless interventional strategy.

Prospective, large‐scale multicenter trial for the use of drug‐coated balloons in coronary lesions: The DCB‐only All‐Comers Registry

Key Points

Discussion

Implication

Cite This Study

Prospective, large‐scale multicenter trial for the use of drug‐coated balloons in coronary lesions: The DCB‐only All‐Comers Registry

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider